COMPARISON
Cetrorelix vs Degarelix
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Cetrorelix is authorised or registered in 10 and Degarelix in 8 of the 10 registers read. Cetrorelix: No trial states a phase. Degarelix: highest phase Phase 3 (7 phase 3 trials, 0 with posted results). 2 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cetrorelix | Degarelix | |
|---|---|---|
| Registered trials differs | 140 clinicaltrials.gov · 2026-10-03 | 187 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: cetrorelix acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: FIRMAGON openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 1999-04-12 ema · 2026-10-03 | 2009-02-17 ema · 2026-10-03 |
| ATC code differs | H01CC02 ema · 2026-10-03 | L02BX02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cetrorelix | placebo | Degarelix | placebo |
|---|---|---|---|---|
| Nasopharyngitis | 8.9% | 8.7% | 4.6% | 5.1% |
| Injection site pain | 8.5% | 3.7% | 8.4% | 0.0% |
| Headache | 7.3% | 7.3% | 2.9% | 5.1% |
| Back pain | 6.2% | 6.4% | 4.9% | 9.2% |
| Hypertension | 4.7% | 5.5% | 6.2% | 7.1% |
| Upper respiratory infection | 6.9% | 6.0% | - | - |
| Diarrhea | 6.0% | 2.8% | - | - |
| Musculoskeletal pain | 6.0% | 2.8% | - | - |
| PSA increased | 5.6% | 2.3% | - | - |
| Arthralgia | 4.2% | 4.6% | - | - |
| Injection site erythema | - | - | 14.1% | 0.0% |
| Injection site induration | - | - | 7.8% | 0.0% |
| Prostatic specific antigen increased | - | - | 4.9% | 6.1% |
| Hot flush | - | - | 4.3% | 0.8% |
| Influenza | - | - | 4.2% | 5.1% |
Trial register Cetrorelix: 2 placebo-controlled trials; Degarelix: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cetrorelix side effects · Degarelix side effects
LEGAL STATUS
Approval in each country read
| Country | Cetrorelix | Degarelix | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
HEAD TO HEAD
2 registered trials include both
| NCT02478775 | Dysregulation of FSH in Obesity: Functional and Statistical Analysis COMPLETED · updated 2024-06-05 |
|---|---|
| NCT01709942 | Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) COMPLETED · updated 2016-04-27 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.